Multiple Genetic Mutations Increase the Risk of Thrombosis Associated With Clopidogrel After Percutaneous Coronary Intervention
Pharmacogenomics · 2023
DOI: 10.2217/pgs-2022-0167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacogenomics, 2023. Verfasst von Hui Jin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, 200240, China. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Thrombosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Fifth People’s Hospital of Shanghai, Shanghai Municipal Health and Family Planning Commission.
Abstract (Originalsprache)
Background
The effect of multiple mutations in CYP2C19, PON1 and ABCB1 genes on the effectiveness and safety of dual antiplatelet therapy after percutaneous coronary intervention remains unclear.
Methods
In total, 263 Chinese Han patients were enrolled in this study. Platelet aggregation rates and thrombosis risk were used to compare clopidogrel responses and outcomes in patients with different numbers of genetic mutations.
Results
Our study demonstrated that 74% of the patients carried more than two genetic mutations. High platelet aggregation rates were associated with genetic mutations in patients receiving clopidogrel and aspirin after percutaneous coronary intervention. Genetic mutations were closely related to the recurrence of thrombotic events, but not bleeding. The number of genes that become dysfunctional in patients is directly correlated with the risk of recurrent thrombosis.
Conclusion
Compared with CYP2C19 alone or the platelet aggregation rate, it is more helpful to predict clinical outcomes by considering the polymorphisms of all three genes. The effects of different combinations of mutations in the genes CYP2C19, PON1 and ABCB1 on the effectiveness and safety of dual antiplatelet therapy in patients who undergo percutaneous coronary intervention (PCI) are unclear. In total, 263 Chinese Han patients receiving 75 mg clopidogrel and 100 mg aspirin daily for 12 months after PCI were enrolled in this study. ADP-induced platelet aggregation rates, thrombosis and bleeding risk were used to compare clopidogrel responses among the patients. Only 3.4% of patients had no mutations in CYP2C19, PON1 or ABCB1, and 74% of patients who chose to be genetically tested carried more than two mutations in these genes. High ADP-induced platelet aggregation rates in patients receiving clopidogrel and aspirin after PCI were associated with mutations in CYP2C19, PON1 and ABCB1. Patients with double or triple genetic mutations in CYP2C19, PON1 or ABCB1 had a higher risk of thrombosis within 18 months of follow-up. We conclude that multiple genetic polymorphisms influence platelet reactivity, bleeding and thrombosis risk during dual antiplatelet therapy after PCI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, 200240, China.
ORCID-Profile: Qing Liang, Guangchun Sun, Yan Yu
Förderung
- Fifth People’s Hospital of Shanghai
- Shanghai Municipal Health and Family Planning Commission
Zitieren
APA
Jin, H., Song, J., Shen, X., Liang, Q., Sun, G., & Yu, Y. (2023). Multiple Genetic Mutations Increase the Risk of Thrombosis Associated With Clopidogrel After Percutaneous Coronary Intervention. Pharmacogenomics. https://doi.org/10.2217/pgs-2022-0167
Vancouver
Jin H, Song J, Shen X, Liang Q, Sun G, Yu Y. Multiple Genetic Mutations Increase the Risk of Thrombosis Associated With Clopidogrel After Percutaneous Coronary Intervention. Pharmacogenomics. 2023. doi:10.2217/pgs-2022-0167
BibTeX
@article{Jin2023,
author = {Jin, Hui and Song, Jinfei and Shen, Xiaoying and Liang, Qing and Sun, Guangchun and Yu, Yan},
title = {Multiple Genetic Mutations Increase the Risk of Thrombosis Associated With Clopidogrel After Percutaneous Coronary Intervention},
journal = {Pharmacogenomics},
year = {2023},
doi = {10.2217/pgs-2022-0167}
}
EUVIMED